Cargando…

Controlled trials needed to prove efficacy and safety of convalescent plasma therapy in coronavirus disease 2019

Detalles Bibliográficos
Autores principales:	Hartog, Nicholas, Holsworth, Amanda, Rajasekaran, Surender
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. 2021
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7642751/ https://www.ncbi.nlm.nih.gov/pubmed/33161152 http://dx.doi.org/10.1016/j.anai.2020.11.005

Ejemplares similares

The art of the possible in approaching efficacy trials for COVID19 convalescent plasma
por: Focosi, Daniele, et al.
Publicado: (2021)

The Assessment of Convalescent Plasma Efficacy against COVID-19
por: Casadevall, Arturo, et al.
Publicado: (2020)

Heterogeneity in COVID‐19 Convalescent Plasma Clinical Trials
por: Müller‐Olling, Mirco, et al.
Publicado: (2021)

Monitoring neutrophil-to-lymphocyte ratio in patients with coronavirus disease 2019 receiving tocilizumab
por: Hartog, Nicholas L., et al.
Publicado: (2021)

Convalescent Plasma Therapy for Coronavirus Disease 2019
por: Choi, Jun Yong
Publicado: (2020)

Convalescent Plasma for Coronavirus Disease 2019: Dose is the Key
por: Yu, Jiangquan, et al.
Publicado: (2021)

The Progress and Challenges of Convalescent Plasma Therapy for Coronavirus Disease 2019
por: Shi, Ming, et al.
Publicado: (2021)

Cytokine and Chemokine Levels in Coronavirus Disease 2019 Convalescent Plasma
por: Bonny, Tania S, et al.
Publicado: (2020)

Convalescent plasma: Would it prove to be magic potion/boon in the current scenario of COVID pandemic?
por: Pathak, Sangeeta
Publicado: (2020)

Convalescent Plasma: The Relay Baton in the Race for Coronavirus Disease 2019 Treatment
por: Ouyang, Jing, et al.
Publicado: (2020)

What is the optimal usage of coronavirus disease 2019 convalescent plasma donations?
por: Focosi, Daniele, et al.
Publicado: (2021)

Convalescent plasma as a treatment modality for coronavirus disease 2019 in Sudan
por: Hassan, Mozan Osman, et al.
Publicado: (2020)

Treatment of Coronavirus Disease 2019 (COVID-19) Patients with Convalescent Plasma
por: Salazar, Eric, et al.
Publicado: (2020)

Effectiveness and Controversy of Convalescent Plasma Therapy for Coronavirus Disease 2019 Patients
por: Shu, Zhanjun, et al.
Publicado: (2021)

Convalescent plasma therapy for coronavirus disease 2019 in ambulatory versus hospitalized patients: Efficacy and risk of thromboembolism
por: Li, Pei Ye, et al.
Publicado: (2023)

Convalescent plasma therapy for COVID-19: a tried-and-true old strategy?
por: Xi, Yongzhi
Publicado: (2020)

Impact of Convalescent Plasma Therapy on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Profile in Coronavirus Disease 2019 (COVID-19) Patients
por: Tang, Juanjie, et al.
Publicado: (2021)

A Randomized Controlled Study Assessing Convalescent Immunoglobulins vs Convalescent Plasma for Hospitalized Patients With Coronavirus 2019
por: Maor, Yasmin, et al.
Publicado: (2023)

Safety and Efficacy of Convalescent Plasma in Elderly COVID-19 Patients: The RESCUE Trial
por: Franchini, Massimo, et al.
Publicado: (2021)

Convalescent plasma therapy: a promising coronavirus disease 2019 treatment strategy
por: Piyush, Ravikant, et al.
Publicado: (2020)

Convalescent plasma for coronavirus disease 2019 in pregnancy: a case report and review
por: Grisolia, Gianpaolo, et al.
Publicado: (2020)

Guidance on the Use of Convalescent Plasma to Treat Immunocompromised Patients With Coronavirus Disease 2019
por: Bloch, Evan M, et al.
Publicado: (2023)

Convalescent Plasma for Patients Hospitalized With Coronavirus Disease 2019: A Meta-Analysis With Trial Sequential Analysis of Randomized Controlled Trials
por: Ling, Ryan Ruiyang, et al.
Publicado: (2022)

The missing pieces in the jigsaw and need for cohesive research amidst coronavirus infectious disease 2019 global response
por: Gupta, Naveen, et al.
Publicado: (2020)

Recruitment Strategy for Potential COVID-19 Convalescent Plasma Donors
por: Andersen, Kylie J., et al.
Publicado: (2020)

Coronavirus 2019 Silver Linings
por: Santosa, Amelia, et al.
Publicado: (2020)

Seasons of Coronavirus Disease 2019
por: Macnofsky, Robin, et al.
Publicado: (2021)

Coronavirus Disease 2019 Convalescent Plasma and the Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Titer
por: Bloch, Evan M, et al.
Publicado: (2021)

Effect of convalescent plasma transfusion on outcomes of coronavirus disease 2019: a meta-analysis with trial sequential analysis
por: Hakim, Sameh M., et al.
Publicado: (2023)

Symptom Duration and Resolution With Early Outpatient Treatment of Convalescent Plasma for Coronavirus Disease 2019: A Randomized Trial
por: Baksh, Sheriza N, et al.
Publicado: (2023)

Convalescent plasma for the treatment of patients with severe coronavirus disease 2019: A preliminary report
por: Omrani, Ali S., et al.
Publicado: (2020)

Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients: A Randomized Clinical Trial
por: Ortigoza, Mila B., et al.
Publicado: (2021)

Randomized controlled trials are not designed to prove the safety of third-generation hydroxyethyl starch for resuscitation: results from a systematic review
por: Hartog, CS, et al.
Publicado: (2010)

Implications of Coronavirus Disease 2019 (COVID-19) Antibody Dynamics for Immunity and Convalescent Plasma Therapy
por: Casadevall, Arturo, et al.
Publicado: (2020)

Convalescent Plasma Therapy in Coronavirus Disease 2019: a Case Report and Suggestions to Overcome Obstacles
por: Im, Jae Hyoung, et al.
Publicado: (2020)

Convalescent Plasma: A Potential Life-Saving Therapy for Coronavirus Disease 2019 (COVID-19)
por: Alghamdi, Ahmed N., et al.
Publicado: (2020)

Successful treatment of a centenarian with coronavirus disease 2019 (COVID-19) using convalescent plasma
por: Kong, Yujie, et al.
Publicado: (2020)

Effects of Treatment of Coronavirus Disease 2019 With Convalescent Plasma in 25 B-Cell–Depleted Patients
por: Gharbharan, Arvind, et al.
Publicado: (2021)

Convalescent plasma as a treatment modality for Coronavirus Disease 2019 in Indonesia: A case reports
por: Thabrani, Achmad, et al.
Publicado: (2021)

Cohort experience of second messenger RNA vaccine dose tolerance after an initial-dose reaction
por: Eastman, Jacqueline, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fvp8g0gkgr0avqtgfkcig4l0ae